The stock of Ocugen Inc (NASDAQ: OCGN) dropped by a margin of 5.23% to eventually settle at about 6.34. The Rosen Law Firm suspects that the company misled its investors and has quickly swung into Investigations.
The law firm expresses concern over the securities claims, outlining that it will soon get to the bottom of the matter in a bid to help the investors. The main challenge is to find out whether or not the company served investors with materially misleading business information.
The firm terms its joint move a class action with the potential of recovering the investor losses. It won’t be the first time that the firm comes to the rescue of investors. It has been performing remarkably since 2013, finding a place in the top four positions every year. It takes great pride in its success in the recovery of millions of investors’ dollars. In 2019, it reached the pinnacle of its success when it managed to secure about $438 million for investors.
Ocugen Inc also finds itself in trouble again, following the Schall Law Firm pursuits against it. The firm seeks to help investors through its investigations. It suspects that the company was involved in the security laws violations.
The firm must dig out the truth about whether or not the company misled investors through false or misleading statements.
The company brings a new official onboard
Ocugen Inc adds an experienced pharmaceutical and biotechnology executive to its team called Michael Shine in other developments. The new official has worked in top positions in leading pharmaceutical companies such as Colgate Oral Pharmaceutical and Novapharm Therapeutics.
The company’s Chief Executive Officer, Dr. Shankar Musunuri, is pleased by the company’s move to bring onboard the new official. He believes that he will be a major contributor to helping them achieve their financial targets.